AR and metastatic prostate carcinoma: Clinically, most patients with metastatic prostate cancer eventually progress to castration-resistant prostate cancer (CRPC) under sustained androgen deprivation and next-generation androgen receptor (AR) pathway inhibition, and many subsequently develop secondary resistance to taxane chemotherapy and immunotherapy [50,102,103].